Natarajan Ravendhran

3.7k citations
30 papers · 923 indexed · 1 hit paper · h-index 13
Topics
Hepatitis C virus research (23 papers)Liver Disease Diagnosis and Treatment (15 papers)Hepatitis B Virus Studies (10 papers)

In The Last Decade

Natarajan Ravendhran

29 papers receiving 900 citations

Hit Papers

Efficacy of boceprevir, an NS3 protease inhibitor, in com...20102026201520202010100200300400500

Peers

Natarajan Ravendhran
Comparison fields: 5 of 56
  • Hepatology 821
  • Epidemiology 767
  • Infectious Diseases 188
  • Rheumatology 86
  • Molecular Biology 56
Replace Ewa Janczewska with:
Ewa Janczewska Poland
David Bernstein United States
Fernando E. Membreno United States
D. Hueppe Germany
Nai‐Jen Hou Taiwan
Kathryn Razavi‐Shearer United States
R. Soffredini Italy
Jaime Enríquez Spain
Stephen Pianko Australia
Leif Bengtsson United States
Natarajan Ravendhran relative to Ewa Janczewska Poland Ewa Janczewska's profile →
Citations per field
00.5×1.6×
Ewa Janczewska · 1×
Citations per year

Countries citing papers authored by Natarajan Ravendhran

Since Specialization
Citations

This map shows the geographic impact of Natarajan Ravendhran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natarajan Ravendhran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natarajan Ravendhran more than expected).

Fields of papers citing papers by Natarajan Ravendhran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natarajan Ravendhran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natarajan Ravendhran. The network helps show where Natarajan Ravendhran may publish in the future.

Co-authorship network of co-authors of Natarajan Ravendhran

This figure shows the co-authorship network connecting the top 25 collaborators of Natarajan Ravendhran. A scholar is included among the top collaborators of Natarajan Ravendhran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natarajan Ravendhran. Natarajan Ravendhran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 59
2 4
3 22
4 5
5 1
6 1
7 2
8 2
9 1
10 18
11 2
12 16
13 2
14 49
15 1
16 4
17 36
18
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trialbreakdown →
515
19 31
20 6

About Natarajan Ravendhran

Natarajan Ravendhran is a scholar working on Hepatology, Epidemiology and Infectious Diseases, having authored 30 papers that have together received 923 indexed citations. Recurring topics across this work include Hepatitis C virus research (23 papers), Liver Disease Diagnosis and Treatment (15 papers) and Hepatitis B Virus Studies (10 papers). The work is most often cited by research in Hepatology (821 citations), Epidemiology (767 citations) and Infectious Diseases (188 citations). Natarajan Ravendhran has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Jonathan McCone, Ira M. Jacobson, Lorenzo Rossaro, Mitchell Davis, Joseph Galati, John M. Vierling, Frank Anderson, Paul Y. Kwo, Raymond A. Rubin and Eric Lawitz. Their work appears in journals such as The Lancet, Gastroenterology and Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026